Home » Archive

Drug Development

Drug Development, News, Syndication, Xconomy »

Afraxis Licenses its Drug Compounds to Roche Subsidiary Genentech

Posted by sandiegobiotech January 29th, 2013 .
No Comments

Afraxis, a San Diego biopharmaceutical founded in 2007, says today it has licensed exclusive global rights for all of its proprietary drug compounds to Genentech, the Roche subsidiary based in South…

[[Click headline to continue reading.]]

More...

Drug Development, News, Syndication, Xconomy »

Sanford-Burnham’s CEO Sees Incredible Opportunity in Move to Roche

Posted by sandiegobiotech January 16th, 2013 .
No Comments

John Reed says his decision to resign as CEO of Sanford-Burnham Medical Research Institute was not planned—but came about with an offer to join the Swiss pharmaceutical giant—and he cited both…

[[Click headline to continue reading.]]

More...

Drug Development, News, Syndication, Xconomy »

After Clinical Trial Setback, San Diego’s MediciNova Sets New Course

Posted by sandiegobiotech January 8th, 2013 .
No Comments

MediciNova (NASDAQ: MNOV) didn’t have much of a fallback strategy last May, when the San Diego biotech reported that a mid-stage trial of bedoradrine sulfate for intravenous treatment of acute asthma…

[[Click headline to continue reading.]]

More...

Drug Development, News, Syndication, Xconomy »

Five Tips for Building a Successful Relationship with the FDA

Posted by sandiegobiotech December 19th, 2012 .
No Comments

I recently led an initiative to communicate more proactively and frequently with the leaders of the FDA about issues specifically related to improving the agency’s focus on innovative biomedical and…

[[Click headline to continue reading.]]

More...

Drug Development, News, Syndication, Xconomy »

Auspex Raises $25M for Longer-Lasting, Deuterium-Based Drugs

Posted by sandiegobiotech November 8th, 2012 .
No Comments

At San Diego’s Auspex Pharmaceuticals, CEO Larry Fritz is overseeing a drug development program based on a fairly simple premise: If an FDA-approved small molecule drug is susceptible to metabolic…

[[Click headline to continue reading.]]

More...

Drug Development, News, Syndication, Xconomy »

San Diego Life Sciences Roundup: Accelrys, AirStrip, Ligand, & More

Posted by sandiegobiotech October 25th, 2012 .
No Comments

It’s been a chockablock week for San Diego’s life sciences community, with buyouts, investment deals, and milestone payments. Here’s our roundup. —Accelrys (Nasdaq: ACCL), the San Diego scientific…

[[Click headline to continue reading.]]

More...

Drug Development, News, Syndication, Xconomy »

Xconomist of the Week: NPS’s Francois Nader Shares Lessons Learned

Posted by sandiegobiotech October 24th, 2012 .
No Comments

NPS Pharmaceuticals (NASDAQ: NPSP) is gearing up for its first FDA approval, a mere 26 years after the company was founded. It is also six years since CEO Francois Nader joined the Bedminster, NJ,…

[[Click headline to continue reading.]]

More...

Drug Development, News, Syndication, Xconomy »

San Diego Life Sciences Roundup: Optimer, Pfenex, OncoSec, & More

Posted by sandiegobiotech October 19th, 2012 .
No Comments

Venture funding for San Diego’s life sciences companies continued to flow at a healthy rate during the third quarter that ended in September, according to data released earlier today. We’ve got that…

[[Click headline to continue reading.]]

More...

Drug Development, News, Syndication, Xconomy »

Kinsella Redux: Charting a Way Back for Life Sciences Startups

Posted by sandiegobiotech September 27th, 2012 .
No Comments

As a man of many talents, Avalon Ventures’ Kevin Kinsella has a tendency to apply a term from one of his fields of interests in a conversation about another. Kinsella’s career as a biotech venture…

[[Click headline to continue reading.]]

More...

Drug Development, News, Syndication, Xconomy »

An Insider’s View on Raising Money from Life Sciences VCs

Posted by sandiegobiotech August 21st, 2012 .
No Comments

The life sciences venture capital industry is undergoing rapid change. Although many innovative ideas have been taken from the bench to scientific discovery to treating patients, funding today to…

[[Click headline to continue reading.]]

More...